Tagged Articles

medication 93 articles

Takeda stands behind type 2 diabetes drug Actos despite reports of bladder cancer

Takeda Pharmaceuticals says it is confident in its type 2 diabetes medication Actos despite studies that show the drug puts users at risk for bladder cancer. The drug company issued a statement following a newly published study that backed up bladder cancer risks brought to light in an earlier study. The new study involved data from more than 115,000 people who were treated with diabetes drugs from 1988 to 2009. Overall, 470 people were diagnosed with bladder cancer during about 4 ½ years of follow up. Diabetics treated with Actos had an 83 percent increased risk of bladder cancer than ... Read More

New diabetes drugs have to provide more proof they are safe

These days, drugs to treat diabetes have one of the highest safety standards to clear before they are granted approval by the Food and Drug Administration (FDA). Placebo-controlled studies are no longer enough to sway agency decision makers. Drug companies must prove their new diabetes treatments won’t cause more problems than the condition they are treating. Which is why excitement over promising data from phase II studies on LY2605541, a joint effort by Eli Lilly and Boehringer Ingelheim, is contained. The drug showed better or equal glycemic control for patients with type 1 or type 2 diabetes than other similar ... Read More

Experimental type 2 diabetes drug shows promise in African American adults

An experimental drug for type 2 diabetes is showing promising results in African American adults in a late-stage clinical trial. The once-daily tablet, marketed by Boehringer Ingelheim as Tradjenta, helped reduce blood sugar levels in patients whose blood sugar had not been previously adequately controlled. It is in a class of medications known as DPP-4 inhibitors, which work different from other diabetes medications by inhibiting glucagon and blood sugar levels. African Americans are at a 77 percent greater risk of developing type 2 diabetes than Caucasians. Nearly 20 percent – or about 4.9 million – African American adults are living ... Read More

Old drug found to be key treatment for non-Hodgkin lymphomas

A drug developed 50 years ago has reemerged as a new weapon in the fight against certain types of non-Hodgkin lymphomas, more than doubling progression-free survival rates and reducing side effects compared to a multi-drug cocktail that for years has been used to treat indolent non-Hodgkin lymphomas. The drug, bendamustine (Treanda), showed promising results when combined with another therapy, rituximab (Rituxan). Traditionally, the disease has been treated with a combination of five different drugs – rituximab, cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine, and prednisone – called R-CHOP. Findings on bendamustine were presented this week at the annual meeting of the American ... Read More

Actos, Avandia more likely to cause bladder cancer than other diabetes drugs

Patients taking a class of medications used to treat type 2 diabetes are far more likely to develop bladder cancer than patients on other types of diabetes drugs, according to a new British study. The study pitted glitazones against sulfonylurea agents, both medications used to treat type 2 diabetes. Glitazones, or thiazolidinediones, work by controlling blood sugar by improving insulin sensitivity. Glitazones on the market today include the popular diabetes treatments pioglitazone (Actos) and rosiglitazone (Avandia). Sulfonylurea agents are in a class known as anti-diabetic agents, and work by helping the pancreas produce more insulin. Sulfonylurea agents include the drug ... Read More

Diabetics urged to avoid Actos due to cancer risk

People with type 2 diabetes should use the drug Actos (pioglitazone) only if all other options have failed, and people with pre-diabetes should never use it, says Consumer Reports, the well-known consumer watchdog organization. Two recent studies found that the drug increases the risk for bladder cancer, particularly in men and with long-term use. The first study involved 193,000 people 40 or older with type 2 diabetes. The second study involved 1.5 million people. The data prompted the Food and Drug Administration (FDA) to issue a safety warning for all drugs that contain the active ingredient pioglitazone. This includes the brand ... Read More

Prescription drug cocktails could be killing our combat veterans

Imagine dutifully serving and surviving your combat tours in the Middle East, only to return home and be killed by a prescription drug. That is apparently what is happening to hundreds of young military veterans coming back to the U.S. from Afghanistan and Iraq with Post-Traumatic Stress Disorder (PTSD) who are being treated with a cocktail of anti-psychotics, anti-depressants, sleeping pills, and other prescription drugs. Stan and Shirley White of Charleston, West Virginia, were coping with the grief of losing their son Bob, a Fort Bragg paratrooper, in Afghanistan, when their other son Andrew, who had returned home from combat ... Read More

Kids with type 2 diabetes have limited treatment options

The rising number of kids being diagnosed with type 2 diabetes has created new challenges on how to manage the “adult-onset” disease in young people, according to concerns raised at a recent meeting of pediatricians in Boston. The staggering increase in type 2 diabetes is a result of increased childhood obesity. About half the new cases of diabetes in teenagers these days is for the type 2 “adult” variety, compared to just three percent decades ago. How to treat these children is what researchers call discouraging. Researchers studied about 700 children over the course of four years. They found that ... Read More

FDA approves new medication for erectile dysfunction

Move over Viagra and Cialis, there’s a new erectile dysfunction drug in town, and it’s name is Stendra. The new drug, made by Vivus, got a nod from the Food and Drug Administration (FDA) just last week. It works in much the same way as its competitors, by inhibiting the same enzyme to increase blood flow to the penis. The drug will provide another option to the nearly 30 million men who suffer from erectile dysfunction, a condition in which men have difficulty getting or keeping an erection. Stendra, also known as avanafil, will come with the same side effect ... Read More

Study finds Enbrel is not an effective back pain treatment

A new back pain medication, initially hailed to be a breakthrough in safe pain management, was found to be no more effective in treating back pain over time than other pain treatments, according to a study published this week in the Annals of Internal Medicine. Back pain affects nearly two-thirds of Americans and is the leading cause of disability in people 45 years of age and younger. Treatment for sciatica, or pain that radiates from the back into the buttocks and legs, typically involves epidural steroid injections that don’t always dull the pain and can put patients at risk for ... Read More